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Leucine-rich repeat (LRR) proteins have recently
been identified as important regulators of synapse
development and function, but formanyLRRproteins
the ligand-receptor interactions are not known. Here
we identify the heparan sulfate (HS) proteoglycan
glypican as a receptor for LRRTM4 using an
unbiased proteomics-based approach. Glypican
bindsLRRTM4,but not LRRTM2, in anHS-dependent
manner. Glypican 4 (GPC4) and LRRTM4 localize to
the pre- and postsynaptic membranes of excitatory
synapses, respectively. Consistent with a trans-
synaptic interaction, LRRTM4 triggers GPC4 clus-
tering in contacting axons and GPC4 induces
clustering of LRRTM4 in contacting dendrites in
an HS-dependent manner. LRRTM4 positively regu-
lates excitatory synapse development in cultured
neurons and in vivo, and the synaptogenic activity
of LRRTM4 requires the presence of HS on the
neuronal surface. Our results identify glypican as an
LRRTM4 receptor and indicate that a trans-synaptic
glypican-LRRTM4 interaction regulates excitatory
synapse development.
INTRODUCTION
Precise synaptic connectivity is essential for the proper function-
ing of neural circuits. Establishing functional synapses between
pre- and postsynaptic neurons requires target cell recognition,
transformationof initial cell-cell contacts into specializedsynaptic
junctions, and their differentiation and maturation into distinct
synapse types (Shen and Scheiffele, 2010; Waites et al., 2005;
Williams et al., 2010). Cell-surface interactions probably play
key roles at each of these steps, but the identity of the surface
molecules involved is only now beginning to be uncovered.
Synaptic adhesion molecules are a key class of cell surface
molecules that orchestrate synaptic connectivity. Besides phys-696 Neuron 79, 696–711, August 21, 2013 ª2013 Elsevier Inc.ically linking and stabilizing pre- and postsynaptic membranes,
synaptic adhesion molecules mediate target recognition, drive
pre- and postsynaptic specialization, and may contribute to
the diversity and plasticity of synapses (Dalva et al., 2007; Yama-
gata et al., 2003). Recent work has identified a wide variety of
trans-synaptic adhesion complexes with partially overlapping
but distinct roles in organizing synapse development. These
include the neuroligins and their binding partners neurexins
(Ichtchenko et al., 1995; Scheiffele et al., 2000), SynCAMs
(Biederer et al., 2002), NGLs and Netrin-Gs/LAR (Kim et al.,
2006; Woo et al., 2009), Slitrks and PTPd (Takahashi et al.,
2012), and LRRTMs (de Wit et al., 2009; Linhoff et al., 2009).
The LRRTMs (leucine-rich repeat transmembrane neuronal
proteins) are of particular interest because LRRTM isoforms
are differentially expressed by neuronal populations in the CNS
(Laure´n et al., 2003), suggesting that they may contribute to
the development of specific synaptic connections. LRRTM1
and LRRTM2 regulate excitatory synapse development by
trans-synaptically interacting with presynaptic neurexins (de
Wit et al., 2009; Ko et al., 2009a; Siddiqui et al., 2010). Whether
all LRRTMs function through the same presynaptic receptor or
whether there is diversity in LRRTM-receptor interactions is
unknown.
Another class of cell surface molecules with a critical role
in organizing neuronal connectivity is the heparan sulfate
proteoglycans (HSPGs). Proteoglycans are cell surface and
extracellular matrix constituents made up of a core protein
and covalently attached glycosaminoglycan (GAG) chains
composed of repeating disaccharide units. The GAG chains
are enzymatically modified to contain highly sulfated domains
that are negatively charged and serve as protein binding
sites (Bernfield et al., 1999). The role of proteoglycans in the
development of neuronal connectivity is best described for
axon pathfinding, where HSPGs modulate axon guidance cue
distribution, availability, and function (de Wit and Verhaagen,
2007; Van Vactor et al., 2006). Less is known about their role in
synapse development, especially in the CNS. Neuromuscular
synapse development is regulated by the secreted HSPG agrin
(Nitkin et al., 1987; reviewed in Sanes and Lichtman, 2001) and
by the Drosophila glypican Dally-like, a GPI-anchored HSPG
(Johnson et al., 2006). In the CNS, overexpression of the
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morphogenesis (Ethell and Yamaguchi, 1999). Secreted forms
of glypican 4 and 6 promote glutamate receptor clustering and
excitatory synapse formation in retinal ganglion cells (Allen
et al., 2012), suggesting that glypican may have synaptic orga-
nizing activity. However, the molecular interactions that mediate
the effects of glypican have not been identified.
Here we used a mass spectrometric approach to compare
LRRTM2 and LRRTM4 binding partners and find that these
proteins have distinct receptor preferences: whereas LRRTM2
primarily binds to neurexins, the preferential binding partners
for LRRTM4 are glypicans. We find that the glypican-LRRTM4
interaction requires HS and can occur in trans. LRRTM4
regulates excitatory synapse development in cultured neurons
and in vivo, and the synaptogenic activity of LRRTM4, but
not of LRRTM2, requires HS. Our data identify glypican as a
receptor for LRRTM4 and indicate that a trans-synaptic
glypican-LRRTM4 interaction regulates excitatory synapse
development.
RESULTS
Unbiased, Proteomics-Based Identification of Glypican
as a Receptor for LRRTM4
The LRRTM genes are expressed in specific and partially
nonoverlapping expression patterns during synaptogenesis
and in the adult brain (de Wit et al., 2009; Laure´n et al., 2003).
During the synaptogenic period from postnatal day (P) 7 to
P14, LRRTM2 and LRRTM4 show complementary expression
patterns in cortex, with LRRTM2 expression restricted to
layer 6 and LRRTM4 mainly expressed in layer 2/3 and layer 5
(Figures 1A and 1B). In the hippocampus, LRRTM2 and LRRTM4
are coexpressed in dentate gyrus (DG) granule cells (Figures 1A
and 1B, arrowheads). Whether different LRRTM family members
expressed in the same neuron signal through the same pre-
synaptic receptor, or whether various LRRTMs have different
mechanisms of action, is unknown. Phylogenetic analysis indi-
cates that human LRRTM2 and LRRTM4 share only 43% amino
acid identity and that LRRTM4 and LRRTM3 are more closely
related to each other than to other LRRTMs (Laure´n et al.,
2003). These observations raised the possibility that LRRTM4
may have a different presynaptic receptor than LRRTM2.
To identify candidate LRRTM4 interactors, we took an unbi-
ased, discovery-based approach. We purified recombinant
ecto-Fc proteins for LRRTM2 and LRRTM4 (Figure 1C) and
used these in a side-by-side comparison to identify interacting
proteins in detergent-solubilized whole-brain homogenate
from 3- to 4-week-old rats by affinity chromatography. Bound
proteins were analyzed by tandem mass spectrometry. In
agreement with previous results (de Wit et al., 2009; Ko et al.,
2009a), the most abundant proteins bound to LRRTM2-Fc
were neurexins (Figure 1D). Surprisingly few neurexin spectra
counts were detected in the mass spectrometry analysis of the
LRRTM4-Fc-bound proteins. Instead, the major surface protein
identified was glypican, a GPI-anchored HSPG (Figure 1D).
Few glypican spectra counts were detected in the LRRTM2-Fc
sample, suggesting that glypican may preferentially interact
with LRRTM4.To validate the mass spectrometry results, we carried out
cell surface binding assays to test binding of LRRTM2 and
LRRTM4 to glypicans. There are six glypican genes in mammals
(GPC1–GPC6) (Bernfield et al., 1999; Filmus et al., 2008), five of
which were detected in our LRRTM4-Fc sample (GPC1, GPC3–
GPC6; Figure S1A available online). We expressed hemaggluti-
nin (HA)-tagged mouse cDNAs for these glypicans in HEK293T
cells and applied LRRTM2-Fc and LRRTM4-Fc proteins to
assess LRRTM binding. LRRTM2-Fc showed no detectable
binding to glypicans but bound to neurexin 1b-lacking splice
site 4 (Nrx1b(-S4)) (Figure 1E). In contrast to LRRTM2-Fc,
LRRTM4-Fc strongly bound to all glypican isofoms tested
(Figure 1F), demonstrating that glypican preferentially interacts
with LRRTM4.
Glypicans have been implicated in synapse development.
The Drosophila glypican Dally-like regulates neuromuscular
synapse development (Johnson et al., 2006), and GPC4 and
GPC6 promote excitatory synapse formation in retinal ganglion
cells (RGCs) (Allen et al., 2012). Since GPC4 is a Dally-like
ortholog (De Cat and David, 2001; Filmus et al., 2008), and
GPC4 (but not GPC6) is strongly expressed in developing
cortex and hippocampus (Figure S1B), we decided to focus
our experiments on GPC4.
To identify the endogenous binding partners of GPC4, we
generated and purified a recombinant GPC4-Fc protein (Fig-
ure 1G), which lacks the GPI anchor and was confirmed to
contain HS by HS disaccharide analysis (data not shown).
Affinity chromatography with GPC4-Fc on detergent-solubilized
crude synaptosomes followed by mass spectrometry resulted
in the identification of LRRTM3 and LRRTM4, but not of
LRRTM1 or LRRTM2 (Figure 1H). The identification of GPC4
and LRRTM4 in reciprocal affinity chromatography experiments
using LRRTM4-Fc or GPC4-Fc, respectively, strongly suggests
that glypican is an endogenous binding partner of LRRTM4.
To verify binding of GPC4 to LRRTMs, we added soluble
GPC4-Fc to myc-LRRTM-expressing 293T cells. GPC4-Fc
bound to myc-LRRTM4 but showed no detectable binding to
myc-LRRTM2 (Figures 1I and 1J), confirming that glypican pref-
erentially interacts with LRRTM4.
In complementary experiments, we examined binding of
LRRTM2 and LRRTM4 to neurexins. As previously reported
(Ko et al., 2009a; Siddiqui et al., 2010), LRRTM2-Fc strongly
bound to Nrx1b(-S4), but not to Nrx1b(+S4) expressed in
293T cells (Figure S1C). LRRTM4-Fc bound to Nrx1b with or
without S4 but did not bind to LPHN3, the receptor for the
LRR protein FLRT3 (O’Sullivan et al., 2012) (Figure S1D). Fc
alone showed no detectable binding to Nrx1b (Figure S1E).
These results show that, unlike LRRTM2, LRRTM4 interacts
with neurexins in an S4-independent manner, suggesting that
LRRTM4 can bind to a broader array of neurexin isoforms than
LRRTM2.
To further explore the interaction of LRRTM proteins with
glypicans and neurexins, we performed Fc pulldown assays in
293T cells. LRRTM4-Fc pulled down HA-GPC4 from cell lysate,
whereas Fc, Nrx1b(-S4)-Fc, or Nrx1b(+S4)-Fc did not interact
with HA-GPC4 (Figure S1F). In reciprocal experiments, GPC4-
Fc pulled down myc-LRRTM4 from cell lysate but did not
bind to FLRT3-myc (Figure S1G), confirming that GPC4 andNeuron 79, 696–711, August 21, 2013 ª2013 Elsevier Inc. 697
Figure 1. Identification of Glypican as a Receptor for LRRTM4
(A and B) In situ hybridizations showing expression of LRRTM2 (A) and LRRTM4 (B) in horizontal rat brain sections (arrowheads indicate DG).
(C) Coomassie-stained SDS-PAGE gel of purified recombinant LRRTM2- and LRRTM4-ecto-Fc proteins.
(D) Identification of glypicans as candidate LRRTM4 interactors by tandem mass spectrometry. LRRTM2-Fc and LRRTM4-Fc proteins were used as bait and
Triton X-100-solubilized whole rat brain homogenate was used as prey. Neurexins (black bars) are the major surface protein identified by LRRTM2-Fc; glypicans
(gray bars) are the major surface proteins identified by LRRTM4-Fc. Bar graph shows total number of spectra in which the identified proteins were found.
(E and F) Cell surface binding assays. LRRTM2-Fc (red) shows no detectable binding to HEK293T cells expressing HA-tagged glypicans (green) (E). LRRTM4-Fc
strongly binds to glypicans (F). Both bind FLAG-Nrx1b(-S4).
(G) Coomassie-stained SDS-PAGE gel of purified recombinant GPC4-Fc protein.
(H) Identification of LRRTM3 and LRRTM4 in GPC4-Fc affinity purification of Triton X-100-solubilized crude synaptosomes.
(I and J) Binding assays. GPC4-Fc (red) does not bind to myc-LRRTM2 (green) (I) but does bind to myc-LRRTM4 (J). See also Figure S1. Scale bar represents
10 mm in (E), (F), (I), and (J).
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displayed a weak interaction with GPC4 (Figures S1F and S1G),
which we did not detect in cell surface binding assays (Figures
1E, 1F, 1I, and 1J). This suggests that LRRTM2 may have a
low affinity for glypican, which would agree with the minor pres-
ence of glypican in the LRRTM2-Fc pulldown (two spectral
counts; Figure 1D). Together, our results indicate that LRRTM4
has two binding partners: neurexin and glypican. Whereas neu-
rexins interact with both LRRTM2 and LRRTM4, glypican is a
preferential binding partner of LRRTM4.698 Neuron 79, 696–711, August 21, 2013 ª2013 Elsevier Inc.Characterization of the GPC4-LRRTM4 Interaction
To determine whether LRRTM4 and GPC4 can interact directly,
we performed cell-free binding assays in which we mixed
recombinant His-tagged LRRTM4 ectodomain with purified
Fc proteins. Fc proteins were precipitated with protein
A/G agarose beads and bound proteins were analyzed by
western blot. His-LRRTM4 coprecipitated with GPC4-Fc and
Nrx1b(-S4)-Fc, but not with Fc or LPHN3-Fc (Figure 2A),
confirming a direct interaction between the LRRTM4 ecto-
domain and GPC4.
Figure 2. The Interaction of LRRTM4 with GPC4 Is Direct and Requires HS
(A) Direct interaction of recombinant His-tagged ecto-LRRTM4 with GPC4-Fc. Fc, GPC4-Fc, Nrx1b(-S4)-Fc, or LPHN3-Fc were mixed with His-LRRTM4,
precipitated, and analyzed by western blot. His-LRRTM4 binds to GPC4-Fc and Nrx1b(-S4)-Fc but not to Fc or LPHN3-Fc.
(B) LRRTM4 bound to Nrx1b(-S4) cannot simultaneously bind to GPC4. Recombinant HA-GPC4, Nrx1b(-S4)-Fc and His-LRRTM4, or His-FLRT3 were mixed and
precipitated with protein A/G agarose. Proteins bound to Nrx1b(-S4)-Fc were analyzed with His and HA antibodies. Blot shows full-length GPC4.
(C) LRRTM4 bound to GPC4 cannot simultaneously bind to Nrx1b(-S4). HA-GPC4, Nrx1b(-S4)-Fc and His-LRRTM4, or His-FLRT3 were mixed and precipitated
with HA affinity matrix. Proteins bound to HA-GPC4 were analyzed with His and Fc antibodies.
(D) Cell surface binding assays. LRRTM4-Fc (red) binding to HA-GPC4 (green) expressing HEK293T cells is strongly reduced in the presence of 0.5 mg/ml HS or
after treatment with 1 U/ml heparinase (hep) III. HS and hepIII abolish background binding of LRRTM4-Fc to cells expressing vector alone.
(E) Quantification of assays in (D). Bar graph showsmean ± SEM; a.u., arbitrary units. Only LRRTM4-Fc binding to HA-GPC4 + vehicle was significantly above the
pDisplay + vehicle control condition (***p < 0.001, post hoc analysis using Bonferroni Multiple Comparisons test; all other comparisons p > 0.05; n = 11–29 cells
per condition).
(F) Schematic representation of HA-GPC4 glycosylation mutants. Green dots indicate proteolytic cleavage site; serine residues serving as HS GAG attachment
sites (red dots) were mutated to alanine (blue dots). Mutation of all three GAG attachment sites strongly reduces binding of LRRTM4-Fc (red) to HA-GPC4 (green).
See also Figure S2. Scale bar represents 10 mm in (D) and (F).
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to its two binding partners, neurexin and glypican. We purified
recombinant HA-GPC4 from HEK293T-conditioned media by
affinity chromatography using HA antibodies (Figure S4A) and
mixed HA-GPC4 with Nrx1b(-S4)-Fc and His-LRRTM4 or His-
FLRT3. We then precipitated neurexin with protein A/G agarose
to test whether pulldown of LRRTM4 bound to neurexin wouldalso bring down glypican. Nrx1b(-S4)-Fc precipitated His-
LRRTM4, but not His-FLRT3. HA-GPC4 did not come down
with neurexin-bound LRRTM4 (Figure 2B). In the reciprocal
experiment, HA-GPC4 was precipitated with HA antibody-
coupled beads to test whether pulldown of LRRTM4 bound to
glypican can bring down neurexin. We found that HA-GPC4
precipitated His-LRRTM4, but not His-FLRT3. Nrx1b(-S4)-FcNeuron 79, 696–711, August 21, 2013 ª2013 Elsevier Inc. 699
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In separate experiments, we further established that Nrx1b(-S4)-
Fc or Nrx1b(+S4)-Fc does not bind to glypican (Figures S1F,
S2A, and S2B). These data suggest that LRRTM4 forms separate
complexes with neurexin and glypican and argue against the
existence of a tripartite complex.
We next investigated the aspects of glypican processing that
are important for LRRTM4 binding. Glypicans consist of a core
protein with a cysteine-rich globular domain and a stalk-like
domain containing three HS GAG attachment sites. Many
glypicans, including GPC4, contain a proteolytic cleavage site
in their cysteine-rich domain (Figure 2F). After cleavage, which
is required for some glypican functions (De Cat et al., 2003),
the two core protein subunits remain bound by disulfide bonds.
GPC4 deletion constructs containing truncations of the core
protein were retained intracellularly or lacked glycosylation and
could not be used in binding assays (data not shown). We there-
fore tested whether proteolytic cleavage is required for GPC4
binding to LRRTM4.We generated HA-GPC4 351-AISA, in which
the protease cleavage consensus sequence R351ISR354 was
mutated to A351ISA354 (Figure S2C) (De Cat et al., 2003). HA-
GPC4 351-AISA was expressed on the cell surface (Figure S2C),
and proteolytic processing of HA-GPC4 351-AISA was abol-
ished as determined by the absence of the 40 kDa N-terminal
proteolytic GPC4 fragment (Figure S2D). Lack of cleavage did
not affect LRRTM4-Fc binding to HA-GPC4 351-AISA (Fig-
ure S2E), suggesting that GPC4 processing is not required for
the interaction with LRRTM4.
To determine the role of GPC4’s HS chains in LRRTM4 bind-
ing, we first tested whether excess HS could block the interac-
tion of LRRTM4 and GPC4. In the presence of HS (0.5 mg/ml),
binding of LRRTM4-Fc to HA-GPC4-expressing 293T cells was
blocked, and background binding to cells expressing the vector
alone was abolished (Figures 2D and 2E). We next determined
whether enzymatic removal of HS would affect LRRTM4 binding
to GPC4. 293T cells were treated with heparinase III (hepIII; 2 hr,
1 U/ml) before applying LRRTM4-Fc. The efficiency of heparin-
ase treatment in removing HS was verified by staining hepIII-
treated cells with 3G10 antibody, which specifically recognizes
the HS stubs generated by enzymatic digestion and shows no
signal in vehicle-treated cells (Figure S2F). Heparinase treatment
strongly reduced binding of LRRTM4-Fc to HA-GPC4 and
abolished background binding (Figures 2D and 2E). In a com-
plementary approach, we mutated the three serine residues
serving as GAG attachment sites to alanines and evaluated
binding of LRRTM4 (Figure 2F). HA-GPC4 lacking all three
GAG attachment sites (HA-GPC4 AAA) showed strongly
reduced glycosylation compared to HA-GPC4 (Figure S2F). All
point mutants were expressed on the cell surface (Figure S2G).
Binding of LRRTM4-Fc to GPC4 lacking single GAG attachment
sites was reduced, and binding to HA-GPC4 AAA was abolished
(Figure 2F). Together, these results demonstrate that the HS
chains in GPC4 are a key determinant of the interaction with
LRRTM4.
LRRTM4 and GPC4 Localize to Glutamatergic Synapses
LRRTM1 and LRRTM2 proteins localize to the postsynaptic
density of excitatory synapses (de Wit et al., 2009; Linhoff700 Neuron 79, 696–711, August 21, 2013 ª2013 Elsevier Inc.et al., 2009), but the distribution of LRRTM4 protein in the
nervous system has not yet been described. To this end,
we developed a monoclonal antibody against a conserved
C-terminal peptide in LRRTM4, in collaboration with the
UCDavis/NIH NeuroMab initiative. Acutely prepared rat
hippocampal slices were mildly fixed and thinly cryosectioned,
and localization of endogenous LRRTM4 was analyzed using
confocal microscopy. In the hippocampus, LRRTM4 immuno-
reactivity was limited to the somata of granule cells and the
molecular layer (Figure 3B, arrowheads). The LRRTM4 transcript
is only expressed in DG granule cells in this region (Figure 3A),
suggesting that LRRTM4 localizes to granule cell dendrites.
An independent, polyclonal antibody against the LRRTM4
ectodomain confirmed a dendritic, punctate distribution in
cultured hippocampal neurons positive for Prox1 (Figure S3A),
a DG granule cell-specific nuclear marker (Williams et al.,
2011). LRRTM4 puncta partially overlapped with the presynaptic
excitatory marker VGlut1 (Figure 3C) and colocalized with the
postsynaptic glutamate receptor subunit GluR1 (Figure 3D).
Staining for the presynaptic inhibitory marker VGAT showed no
colocalization of LRRTM4 and VGAT (Figure S3B). These data
suggest that endogenous LRRTM4 localizes to the postsynaptic
density of glutamatergic synapses.
The localization of GPC4 protein in the nervous system during
the postnatal synaptogenic period has not been characterized.
In situ hybridizations showed that GPC4 mRNA is highly
expressed in DG and CA1 neurons, and to a lesser extent in
CA3 neurons (Figure 3E; Figure S1B). Labeling of hippocampal
cryosections with a polyclonal GPC4 antibody (Ford-Perriss
et al., 2003; Siebertz et al., 1999) revealed prominent staining
of DG and CA1 cell bodies and dense labeling of the neuropil
(Figure 3F). The mRNA and protein expression patterns indicate
that GPC4 has a much broader distribution in the CNS than
LRRTM4, suggesting that GPC4 has additional roles besides
those mediated by LRRTM4 interaction.
To determinewhether GPC4 is a synaptic protein, we analyzed
GPC4 distribution in hippocampal neurons. GPC4 localized
to discrete puncta, which colocalized with VGlut1 and were
juxtaposed to puncta positive for the postsynaptic excitatory
marker PSD-95 (Figure 3G), suggesting a presynaptic localiza-
tion of GPC4. To test whether GPC4 shows a similar distribution
in vivo, we took advantage of the strong GPC4 signal in CA3
stratum lucidum (Figure 3F, arrowheads), where large GPC4-
positive puncta colocalized with VGlut1 (Figure S3C). GPC4/
VGlut1-positive puncta were juxtaposed to PSD-95 puncta,
suggesting that GPC4 also localizes to excitatory presynaptic
terminals in vivo. GPC4 showed little colocalization with the
pre- and postsynaptic inhibitory markers VGAT and gephyrin
(Figure S3D). Together, these results indicate that LRRTM4
and GPC4 localize to glutamatergic synapses, consistent with
GPC4 being a presynaptic binding partner for postsynaptic
LRRTM4.
LRRTM4 and GPC4 Interact In trans
The distribution of LRRTM4 and GPC4 proteins in hippocampal
neurons suggests that they localize to opposite sides of
the glutamatergic synapse. To test whether GPC4 and
LRRTM4 can interact in trans, we transfected HEK293T cells
Figure 3. Endogenous LRRTM4 and GPC4 Proteins Localize to Excitatory Synapses
(A) In situ hybridization showing LRRTM4 expression in a sagittal section of P14 rat hippocampus. LRRTM4 expression is limited to DG granule cells.
(B) LRRTM4 protein (red) localizes to granule cell bodies and the DGmolecular layer in P15 hippocampus (arrowheads). The presynaptic excitatorymarker VGlut1
(blue) visualizes hippocampal architecture.
(C and D) Postsynaptic localization of LRRTM4 in DIV14 hippocampal neurons. (C) LRRTM4-positive puncta (red) partially overlap with VGlut1 puncta (green).
(D) LRRTM4 puncta (red) colocalize with the excitatory postsynaptic marker GluR1 (green).
(E) In situ hybridization showing GPC4 expression in a sagittal section of P14 hippocampus. GPC4 is strongly expressed in DG and CA1 and weakly in CA3.
(F) GPC4 protein (red) localizes to DG and CA1 cell bodies and neuropil in P21 hippocampus. Arrowheads indicate strong GPC4 staining in CA3 stratum lucidum.
(G) Presynaptic localization of GPC4 in DIV16 hippocampal neuron. GPC4-positive puncta colocalize with VGlut1 (red) and are juxtaposed to puncta positive for
the excitatory postsynaptic marker PSD-95 (blue). See also Figure S3. Scale bar represents 200 mm in (A), (B), (E), and (F) and 10 mm in (C), (D), and (G).
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Figure 4. trans-Cellular GPC4-Mediated Clustering of Endogenous LRRTM4 Requires HS
Coculture assays.
(A) Myc-LRRTM4 (green) expressed in HEK293T cells cocultured with DIV7–DIV8 hippocampal neurons induces clustering of the presynaptic excitatory marker
VGlut1 (red) but not of the presynaptic inhibitory marker VGAT (red).
(B) Quantification of assays in (A). LRRTM4 significantly increases the fractional VGlut1 area (area occupied by VGlut1 staining per myc-labeled surface area
normalized to GFP-expressing control cells) compared to GFP cells (VGlut1: GFP 1.00 ± 0.32 [n = 30 cells] versus LRRTM4 14.18 ± 2.54 [n = 27]; ***p < 0.0001,
Mann-Whitney test. VGAT: GFP 1.00 ± 0.22 [n = 21 cells] versus LRRTM4 2.07 ± 0.54 [n = 23]; n.s. p = 0.1103 Mann-Whitney test).
(C) Myc-LRRTM4 induces clustering of endogenous GPC4 (red).
(D) Quantification of (C); GFP 1.00 ± 0.34 (n = 19 cells) versus LRRTM4 22.67 ± 4.52 (n = 24); ***p < 0.0001, Mann-Whitney test.
(E) HA-GPC4 expressed in 293T cells induces clustering of the excitatory postsynaptic marker PSD-95 (red; arrowheads) but not of the inhibitory postsynaptic
marker gephyrin (red).
(F) Quantification of (E); PSD-95: GFP 1.00 ± 0.21 (n = 18) versus HA-GPC4 5.30 ± 0.58 (n = 26); ***p < 0.0001, Student’s t test. Gephyrin: GFP 1.00 ± 0.23 (n = 20)
versus HA-GPC4 1.96 ± 0.81 (n = 25); n.s. p = 0.7441, Student’s t test.
(G) HA-GPC4-mediated clustering of endogenous LRRTM4 (red) in contacting dendrites requires GAG chains. HA-GPC4-mediated LRRTM4 clustering
(arrowheads) is absent around HA-GPC4 AAA-expressing cells.
(H) Quantification of (G); GFP 1.00 ± 0.22 (n = 53), HA-GPC4 15.06 ± 3.07 (n = 78), HA-GPC4 AAA 2.17 ± 0.52 (n = 53); ***p < 0.001, Kruskal-Wallis test, Dunn’s
multiple comparisons post hoc test. Bar graphs show mean ± SEM. See also Figure S4. Scale bar represents 10 mm in (A), (C), (E), and (G).
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could induce clustering of their respective binding partners in
cocultured hippocampal neurons. Myc-LRRTM4 expressed in
293T induced strong clustering of the presynaptic marker VGlut1
but not of VGAT (Figures 4A and 4B). Endogenous neuronal
GPC4 also clustered on the surface of LRRTM4-expressing
cells, whereas GFP-expressing cells had no such effect (Figures
4C and 4D). We then performed the reciprocal experiment using
HA-GPC4-expressing 293T cells and analyzed clustering of
synaptic markers in contacting dendrites. HA-GPC4 had a
small but significant effect on PSD-95 aggregation in dendrites
compared to GFP control cells but did not induce gephyrin
clustering (Figures 4E and 4F). Endogenous LRRTM4 clusters
also accumulated opposite to HA-GPC4-expressing 293T cells
(Figures 4G and 4H), indicating that GPC4 induces clustering702 Neuron 79, 696–711, August 21, 2013 ª2013 Elsevier Inc.of LRRTM4 in opposing membranes. Since the GPC4-LRRTM4
interaction requires HS (Figures 2D–2F), expression of GPC4
lacking GAG attachment sites in 293T cells should not induce
aggregation of LRRTM4 in cocultured neurons. Consistent with
this prediction, the HA-GPC4 AAA mutant did not induce clus-
tering of LRRTM4 (Figures 4G and 4H). These results indicate
that GPC4 and LRRTM4 can interact in trans in anHS-dependent
manner.
Upon expression in cell lines, GPC4 is constitutively released
from the cell surface and secreted into the culture media
(Watanabe et al., 1995). To determine whether soluble GPC4
can induce clustering of LRRTM4 and trigger postsynaptic
differentiation similar to surface-expressed GPC4, we purified
recombinant HA-GPC4 from 293T-conditioned media and
bath applied it to cultured hippocampal neurons. Purified
Neuron
Synapse Organizer LRRTM4 Acts via HSPG GlypicanHA-GPC4 (Figure S4A) directly bound the LRRTM4 ectodomain
in cell-free binding assays (Figure 2C and data not shown).
We applied recombinant HA-GPC4 to DIV13 neurons for 24 hr
at a concentration of 10 nM, within the effective range for soluble
GPC4-induced glutamate receptor clustering in RGCs (0.1–
10 nM; Allen et al., 2012), and quantified density and area of
LRRTM4-positive clusters per length of MAP2-positive dendrite.
Since hippocampal LRRTM4 expression is limited to DG granule
cells, we only included Prox1-positive neurons in our analysis.
The density and area of LRRTM4 clusters did not differ between
HA-GPC4- and Fc-treated neurons (Figures S4B–S4D). Treat-
ment with 10 nM preclustered GPC4-Fc did not affect density
and area of LRRTM4 clusters either (Figures S4E–S4G), suggest-
ing that soluble GPC4 does not induce clustering of LRRTM4 on
the dendritic surface.
To determine whether soluble GPC4 can induce postsynaptic
differentiation, we treated hippocampal neurons with 1 or 10 nM
HA-GPC4 for 6 days and quantified the density of VGlut1/PSD-
95-positive puncta. In contrast to RGCs (Allen et al., 2012),
6-day treatment with soluble HA-GPC4 did not increase excit-
atory synapse density in DIV14 hippocampal neurons (Figures
S4H and S4I). Since the peak of synaptogenesis may occur
earlier in hippocampal neurons compared to RGCs (Xu et al.,
2010), we also added recombinant HA-GPC4 from DIV5–DIV8
to determine whether GPC4 may promote synaptogenesis in
immature neurons. Treatment with 1 or 10 nM HA-GPC4 did
not affect excitatory synapse density at this earlier time point
(Figures S4J and S4K). These results indicate that soluble
GPC4 does not induce LRRTM4 clustering or postsynaptic
differentiation in hippocampal neurons and suggest that a
local concentration of GPC4 is needed to aggregate LRRTM4.
Alternatively, the amounts of soluble GPC4 in the culture media
may be saturating, such that exogenous addition does not
increase synapse formation.
LRRTM4 Regulates Functional Excitatory Synapse
Development in Hippocampal Neurons
The experiments described above support a ligand-receptor
relationship between LRRTM4 and glypican, and a potential
role of this interaction in excitatory synapse development. To
directly examine whether LRRTM4 regulates excitatory synapse
formation, we analyzed the consequences of overexpressing
LRRTM4 in cultured hippocampal neurons. Myc-LRRTM4
overexpression from DIV7 to DIV14 significantly increased the
density of excitatory synapses compared to GFP-expressing
control neurons (Figures 5A and 5B). Quantification of VGAT/
gephyrin-positive puncta in sister cultures showed no effect of
LRRTM4 overexpression on inhibitory synapse density (Figures
5C and 5D). To test whether endogenous LRRTM4 contributes
to excitatory synapse development, we designed a short
hairpin RNA (shRNA) to specifically reduce LRRTM4 expression.
The LRRTM4 shRNA effectively reduced mouse myc-LRRTM4
expression in HEK293T cells, whereas expression of shRNA-
resistant human myc-LRRTM4 was not affected (Figure S5A).
Expression of endogenous LRRTM4, but not of LRRTM2,
was strongly reduced in hippocampal neurons infected with
lentivirus containing shLRRTM4 (Figures S5B and S5C).
Furthermore, LRRTM4 immunoreactivity was strongly reducedin shLRRTM4-expressing Prox1-positive neurons, but not in
neighboring, nonelectroporated cells (Figure S5D). Knockdown
of LRRTM4 in Prox1-positive hippocampal neurons using this
shRNA resulted in a 40% decrease in the density of excitatory
synapses, which could be rescued by coexpressing human
myc-LRRTM4 (Figures 5E and 5F). Expression of shLRRTM4 in
Prox1-positive hippocampal neurons did not affect the density
of inhibitory synapses (Figures 5G and 5H), indicating that
endogenous LRRTM4 selectively regulates the density of excit-
atory synapses.
To determine whether the decrease in excitatory synapse
density after LRRTM4 knockdown corresponds to a decrease
in functional synapses, we recorded miniature excitatory and
inhibitory postsynaptic currents (mEPSCs and mIPSCs, respec-
tively) in hippocampal neurons (Figures 5I and 5J). LRRTM4
knockdown significantly decreased mEPSC frequency but did
not change mEPSC amplitude compared to control cells, and
these effects could be rescued by coexpressing human LRRTM4
(Figures 5K and 5L). Frequency and amplitude of mIPSCs were
not affected by knockdown of LRRTM4 (Figures 5M and 5N).
These results are consistent with the selective reduction in
excitatory synapse density after LRTM4 knockdown, as as-
sessed by immunofluorescence.
In a complementary, shRNA-independent approach to
assess the role of LRRTM4 in synapse development, we treated
hippocampal neurons with excess LRRTM4-Fc to competitively
disrupt the trans-synaptic interaction of LRRTM4 with presynap-
tic receptors. Neurons were treated for 6 days and the density of
VGlut1/PSD-95-positive puncta in Prox1-positive cells was
analyzed at DIV14. LRRTM4-Fc treatment reduced excitatory
synapse density by 40% compared to cells treated with Fc
control protein, similar to treatment with LRRTM2-Fc (Figure 5O).
These results are in agreement with the effects of LRRTM4
knockdown, supporting a role of LRRTM4 in regulating excit-
atory synapse development.
LRRTM4’s Synaptogenic Activity Requires Heparan
Sulfate
LRRTM2 and LRRTM4 share a similar synaptogenic activity in
hippocampal neurons, but LRRTM4 is distinct from LRRTM2 in
that it has two presynaptic binding partners, neurexin and glypi-
can. To begin assessing the role of these two LRRTM4 receptors
in synapse development, we tested whether excess GPC4-Fc or
Nrx1b(-S4)-Fc could block excitatory synapse formation in
Prox1-positive neurons. In agreement with previous results
(Chih et al., 2006), 6-day treatment with Nrx1b(-S4)-Fc caused
a reduction in excitatory synapse density in DIV14 hippocampal
neurons (Figures S6A and S6B). However, GPC4-Fc did not
affect excitatory synapse density at this time point nor did
3-day treatment with GPC4-Fc in immature neurons (Figures
S6A–S6D). Possibly, neurexin can compensate when the
glypican-LRRTM4 interaction is blocked. Alternatively, since
LRRTM4-Fc decreases excitatory synapse density (Figure 5O),
but GPC4-Fc does not (Figure S6), it could be that GPI-anchored
glypican is only part of a functional presynaptic LRRTM4
receptor and requires a yet unidentified transmembrane
signaling coreceptor. Such signaling might be required for the
development of synaptic contacts between neurons.Neuron 79, 696–711, August 21, 2013 ª2013 Elsevier Inc. 703
(legend on next page)
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Synapse Organizer LRRTM4 Acts via HSPG GlypicanWe next analyzed whether excess HS could interfere with
LRRTM4-mediated synapse formation onto heterologous cells.
HEK293T cells expressing myc-LRRTM2 or myc-LRRTM4
were cocultured with DIV7 hippocampal neurons for 12 hr in
the presence of 0.5 mg/ml HS. Exogenous HS did not affect
LRRTM2-mediated presynaptic differentiation but abolished
the synaptogenic activity of LRRTM4 (Figures 6A–6D). To test
whether LRRTM4-mediated presynaptic differentiation requires
endogenous HS, we treated DIV7 neurons with heparinase III
(2 hr, 1 U/ml), washed and cocultured them for an additional
8 hr with 293T cells expressing myc-LRRTM. Staining with the
3G10 HS stub antibody confirmed the efficiency of hepIII treat-
ment in hippocampal neurons (data not shown). Enzymatic
removal of HS did not affect LRRTM2’s ability to instruct presyn-
aptic differentiation (Figures 6E and 6F) but strongly reduced
LRRTM4’s synaptogenic activity (Figures 6G and 6H). These
results indicate that LRRTM4-mediated presynaptic differen-
tiation requires the presence of HS.
To analyze the relative contributions of glypican and neurexin
to LRRTM4’s synaptogenic activity, we cocultured 293T cells
expressing myc-LRRTM with DIV7 neurons for 12 hr in the
presence of excess Fc, Nrx1b(-S4)-Fc, or GPC4-Fc. GPC4-Fc
did not affect LRRTM2-mediated presynaptic differentiation
but markedly reduced LRRTM4’s synaptogenic activity (Figures
6I–6L), suggesting that GPC4 is a presynaptic receptor for
LRRTM4-induced synapse formation. Unexpectedly, and in
contrast to a previous report (Ko et al., 2009a), two indepen-
dently generated batches of Nrx1b(-S4)-Fc did not reduce
LRRTM2’s synaptogenic activity in three separate experiments
(Figures 6I and 6J). A compensatory role of a-neurexins (Ko
et al., 2009b), or rapid internalization of Nrx-Fc in cocultures
(Chubykin et al., 2005), might explain the lack of effect of
Nrx1b(-S4)-Fc on LRRTM2-induced presynaptic differentiation.
These experiments suggest that LRRTM4 interacts with a
presynaptic HSPG to induce synapse formation. To determineFigure 5. LRRTM4 Regulates Functional Excitatory Synapse Density in
(A) Overexpression of myc-LRRTM4 from DIV7–DIV14 increases excitatory syna
(B) Quantification of the number of VGlut1/PSD-95-positive puncta per length of
versus LRRTM4 1.42 ± 0.09 [n = 35]; ***p < 0.0001, Student’s t test).
(C) Overexpression of myc-LRRTM4 does not affect inhibitory synapse density.
(D) Quantification of normalized VGAT/gephyrin-positive puncta density (GFP 1.
t test).
(E) LRRTM4 knockdown reduces excitatory synapse density, which is rescued b
(F) Quantification of normalized VGlut1/PSD-95 puncta density in Prox1-positive c
0.05 [n = 35]; ***p < 0.001, ANOVA, Tukey-Kramer multiple comparisons post ho
(G) LRRTM4 knockdown does not affect inhibitory synapse density.
(H) Quantification of normalized VGAT/gephyrin puncta density in Prox1-positive
1.04 ± 0.07 [n = 27]; p = 0.7419, ANOVA).
(I and J) ExamplemEPSC (Vhold80mV) (I) andmIPSC traces (Vhold 0mV) (J) from n
human LRRTM4 (rescue, gray).
(K) LRRTM4 knockdown reduces meanmEPSC frequency (values normalized to c
0.90 ± 0.17 [n = 19]; **p < 0.01, Kruskal-Wallis test, Dunn’s multiple comparison
(L) MeanmEPSC amplitude is not affected by LRRTM4 knockdown (normalized va
0.04 [n = 19]; p = 0.7248, ANOVA).
(M and N) Neither mIPSC frequency (control 0.44 ± 0.07 Hz [n = 18] versus shLR
differs between conditions (control 18.31 ± 0.78 pA [n = 18] versus shLRRTM4 1
(O) DIV9–DIV14 treatment with 10 mg/ml LRRTM2- or LRRTM4-Fc reduces excitat
0.50 ± 0.06 (n = 20), LRRTM4-Fc 0.61 ± 0.05 (n = 28); ***p < 0.001, ANOVA, Tuke
show mean ± SEM. Scale bar represents 10 mm in (A), (C), (E), and (G).whether HS is required presynaptically, we first tested a large
number of shRNAs to knock down expression of EXT1 and
EXT2, the two key enzymes in heparan sulfate synthesis. Howev-
er, expression of two working EXT1 shRNAs in hippocampal
neurons resulted in the fasciculation of neurites and retraction
of neurites from the substrate, effects not seen in neurons ex-
pressing the control vector or shRNAs against other targets.
We therefore determinedwhether glypican is required in neurons
for LRRTM4-induced synapse formation. We designed an
shRNA against mouse and rat GPC4 and an shRNA-resistant
GPC4 rescue construct containing silent mutations in the
shRNA target region (GPC4*) and confirmed knockdown and
rescue of GPC4 expression in 293T cells (Figure S6E). We then
electroporated hippocampal neurons with control, shGPC4, or
shGPC4 and GPC4* plasmids, cocultured 293T cells expressing
myc-LRRTM at DIV7, and quantified the area of synapsin clus-
ters per GFP-positive axon area on the 293T cell surface.
Neuronal knockdown of GPC4 did not affect synapse formation
onto LRRTM2-expressing cells (Figures 6M and 6N) but strongly
reduced synapse formation onto LRRTM4-expressing HEK293T
cells (Figures 6O and 6P). This decrease could be rescued by
coexpression of shRNA-resistant GPC4* (Figures 6O and 6P).
The selective effect of GPC4 knockdown on LRRTM4-, but not
on LRRTM2-mediated presynaptic differentiation, and the
complete rescue by GPC4* support the specificity of the shRNA
used. Taken together, these data indicate that LRRTM4’s
synaptogenic activity depends on presynaptic glypican.
LRRTM4 Regulates Synapse Development in L2/3
Pyramidal Neurons In Vivo
In the final series of experiments, we examined whether loss of
LRRTM4 affects synapse development in vivo. LRRTM4 is
coexpressed with other LRRTM proteins in some neuronal
populations, but whether LRRTM4 serves a unique or redundant
role in synapse development or function is not known. SinceHippocampal Neurons
pse density.
dendrite normalized to GFP control neurons (GFP 1.00 ± 0.06 [n = 36 neurons]
00 ± 0.07 [n = 37] versus LRRTM4 0.99 ± 0.07 [n = 36]; p = 0.9315, Student’s
y coexpression of shRNA-resistant human LRRTM4.
ells (control 1.00 ± 0.04 [n = 34], shLRRTM4 0.63 ± 0.05 [n = 35], rescue 0.91 ±
c test).
neurons (control 1.00 ± 0.05 [n = 27], shLRRTM4 0.97 ± 0.09 [n = 28], rescue
eurons expressing sh-vector (control, black), shLRRTM4 (red), or shLRRTM4+
ontrol cells: control 1.00 ± 0.13 [n = 35], shLRRTM4 0.64 ± 0.10 [n = 41], rescue
s test).
lues: control 1.00 ± 0.02 [n = 35], shLRRTM4 1.00 ± 0.03 [n = 41], rescue 1.03 ±
RTM4 0.36 ± 0.07 Hz [n = 18]; p = 0.42, Student’s t test) nor mIPSC amplitude
6.63 ± 0.81 pA [n = 18]; p = 0.14, Student’s t test).
ory synapse density in Prox1-positive cells (Fc 1.00 ± 0.06 (n = 28), LRRTM2-Fc
y-Kramer multiple comparisons post hoc test). See also Figure S5. Bar graphs
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Figure 6. The Synaptogenic Activity of LRRTM4, but Not of LRRTM2, Requires HS
Coculture assays.
(A) Myc-LRRTM2-induced clustering of synapsin puncta on the HEK293T cell surface in vehicle- or HS (0.5 mg/ml)-treated cocultures.
(B) Quantification of synapsin immunoreactivity as a measure of presynaptic differentiation in assays in (A); vehicle 1.00 ± 0.14 (n = 29 cells) versus HS 1.14 ± 0.22
(n = 30); p = 0.9784, Mann-Whitney test.
(C) HS blocks myc-LRRTM4-induced presynaptic differentiation.
(D) Quantification of (C); vehicle 1.00 ± 0.13 (n = 31) versus HS 0.14 ± 0.03 (n = 34); ***p < 0.0001, Mann-Whitney test.
(E) Myc-LRRTM2-induced presynaptic differentiation in vehicle- or hepIII (1 U/ml)-treated cultures.
(F) Quantification of (E); vehicle 1.00 ± 0.09 (n = 25) versus hepIII 0.91 ± 0.09 (n = 25); p = 0.4676, Student’s t test.
(G) HepIII treatment strongly reduces myc-LRRTM4-induced presynaptic differentiation.
(H) Quantification of (G); vehicle 1.00 ± 0.10 (n = 27) versus hepIII 0.23 ± 0.03 (n = 35); ***p < 0.0001, Student’s t test.
(legend continued on next page)
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Synapse Organizer LRRTM4 Acts via HSPG GlypicanLRRTM4 is highly expressed in DG, we initially injected lentiviral
vectors expressing shLRRTM4 in rat DG at P5 and recorded from
neighboring infected and noninfected granule cells in P13–P16
acute slices, while stimulating their perforant path inputs. In
granule cells, knockdown of LRRTM4 did not affect the strength
of glutamatergic transmission (data not shown), which could
be due to incomplete knockdown or the expression of other
LRRTMs (Laure´n et al., 2003), which may functionally com-
pensate. We therefore decided to investigate LRRTM4’s role in
synapse development in cortical layer 2/3 (L2/3) pyramidal
neurons, which do not express LRRTM2 (Figure 1A). We first
tested whether LRRTM4 regulates synapse formation in cultured
cortical neurons and found a significant decrease in the density
of dendritic spines and of PSD-95-positive spines after LRRTM4
knockdown (Figures S7A–S7D). Embryonic day 15.5 mouse
embryos were electroporated with control or shLRRTM4 plas-
mids, resulting in the transduction of L2/3 pyramidal neurons
in primary somatosensory cortex (Figure 7A). We verified by
in situ hybridization that LRRTM4 is expressed in mouse P15
L2/3 neurons and thatGPC4 is expressed in L2/3 and L4 neurons
(Figures S7E and S7F), indicating that GPC4 is presynaptic to
the neurons we recorded from. GFP-positive electroporated
L2/3 cells were scattered among amajority of nonelectroporated
cells and targeted for whole-cell recording (Figure 7B). We re-
corded mEPSCs from labeled cells in acute brain slices and
compared mEPSCs from control, GFP-expressing neurons to
shLRRTM4-electroporated neurons (Figure 7C). Knockdown of
LRRTM4 did not affect the frequency of mEPSCs (Figure 7D)
but significantly reduced the mean amplitude of mEPSCs (Fig-
ure 7E). These results indicate that LRRTM4 regulates the
strength of glutamatergic synaptic transmission in cortical neu-
rons in vivo, most likely by regulating AMPA receptor content
at synapses.
To determine whether LRRTM4 may regulate synapse density
in vivo as it does in cultured hippocampal and cortical neurons,
we analyzed the density of dendritic spines in L2/3 cortical
neurons in electroporated mice at P14. LRRTM4 knockdown
resulted in a significant, 18% decrease in the density of dendritic
protrusions relative to control neurons (Figures 7F and 7G).
Together, these results indicate that endogenous LRRTM4 is
required for synapse development in vivo.
DISCUSSION
Cell-surface interactions play key roles in establishing functional
neural circuits. Here we identify glypican as an LRRTM4 receptor
in an unbiased, proteomics-based approach to find the endo-
genous receptors for LRRTM2 and LRRTM4. Glypican pre-(I) Effect of Fc, GPC4-Fc, and Nrx1b(-S4)-Fc proteins (50 mg/ml) on LRRTM2-ind
(J) Quantification of (I) (Fc 1.00 ± 0.11 [n = 28], GPC4-Fc 1.05 ± 0.13 [n = 27], Nr
(K) GPC4-Fc reduces myc-LRRTM4-induced presynaptic differentiation.
(L) Quantification of (K); Fc 1.00 ± 0.10 (n = 30), GPC4-Fc 0.30 ± 0.05 (n = 33), Nrx
Kruskal-Wallis test, Dunn’s multiple comparison post hoc test.
(M) Neuronal GPC4 knockdown does not affect synapse formation onto LRRTM
(N) Quantification of (M); control 1.00 ± 0.09 (n = 19) versus shGPC4 1.14 ± 0.24
(O) GPC4 knockdown decreases synapse formation onto LRRTM4-expressing c
(P) Quantification of (O); control 1.00 ± 0.15 (n = 24), shGPC4 0.47 ± 0.10 (n = 30
comparison post hoc test. See also Figure S6. Bar graphs show mean ± SEM. Sferentially interacts with LRRTM4, and this interaction is HS
dependent. GPC4 and LRRTM4 localize to opposing mem-
branes of glutamatergic synapses. GPC4 and LRRTM4 ex-
pressed on the surface of nonneuronal cells induce clustering
of their respective binding partners in cocultured neurons,
supporting a trans-synaptic interaction of presynaptic glypican
and postsynaptic LRRTM4. Overexpression, knockdown, and
competition experiments with soluble LRRTM4 ectodomains
show that LRRTM4 regulates excitatory synapse development
in cultured hippocampal neurons. The synaptogenic activity of
LRRTM4, but not of LRRTM2, requires HS. Knockdown of
LRRTM4 in vivo decreases the strength of glutamatergic synap-
tic transmission and the density of dendritic spines, indicating
that LRRTM4 controls synapse development in vivo. These re-
sults identify glypican as a receptor for LRRTM4 and highlight
the diversity in ligand-receptor interactions that regulate excit-
atory synapse development.
LRRTM4 Binds to HS GAGs
Glypican binding to LRRTM4 requires HS, and HS is required for
LRRTM4 function. Binding of GAGs to LRR proteins is not
unprecedented: a recent study identified chondroitin sulfate
(CS) proteoglycans as ligands for the Nogo receptor familymem-
bers NgR1 and NgR3 (Dickendesher et al., 2012). Interestingly,
NgR1 and NgR3 showed strong selectivity toward specific CS
GAG types, suggesting that differences in GAG sulfation
patterns may regulate NgR binding. Synaptic transmission at
the Drosophila neuromuscular junction is differentially affected
by knockdown of two different enzymes that regulate HSPG
sulfation (Dani et al., 2012), suggesting that HS modifications
are also important for synapse development. Whether LRRTM4
displays any selectivity with regard tomodifications of HS chains
is unknown.
Glypicans are widely expressed throughout the body and bind
many secreted and surface-bound proteins (Bernfield et al.,
1999; Van Vactor et al., 2006). Based on mRNA and protein
expression patterns, it appears likely that LRRTM4 is not the
only endogenous binding partner of GPC4, as LRRTM4 expres-
sion is much more restricted than that of GPC4. The full comple-
ment of synaptic GPC4 interactors is not yet known. In addition
to LRRTM4, our GPC4-Fc pulldown experiment also identified
LRRTM3, a largely uncharacterized LRRTM family member.
LRRTM3 and LRRTM4 are more closely related to each other
than to LRRTM1 and LRRTM2 (Laure´n et al., 2003), and this
evolutionary relationship appears to be reflected in LRRTM-re-
ceptor interactions.
Our experiments suggest that GPC4 needs to aggregate
on the cell surface before it can induce LRRTM4 clusteringuced presynaptic differentiation.
x1b(-S4)-Fc 1.04 ± 0.10 [n = 30]; p = 0.9511, ANOVA).
1b(-S4)-Fc 1.83 ± 0.27 (n = 27); ***p < 0.001; Fc versus Nrx1b(-S4)-Fc p > 0.05;
2-expressing 293T cells. Synapsin (syn), red; GFP, green; myc, blue.
(n = 17); p = 0.7934, Mann-Whitney test.
ells.
), rescue 0.96 ± 0.17 (n = 32); **p < 0.01, Kruskal-Wallis test, Dunn’s multiple
cale bar represents 10 mm in (A), (C), (E), (G), (I), (K), (M), and (O).
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Figure 7. LRRTM4 Regulates Synapse Development in L2/3 Pyrami-
dal Neurons In Vivo
(A) GFP epifluorescence and DIC images from somatosensory cortex slices of
2-week-old mouse brain electroporated in utero at E15–E16. Note GFP
expression in L2/3 and barrels in L4.
(B) High-magnification image of a recording from an electroporated GFP-
positive L2/3 pyramidal neuron surrounded by nonelectroporated cells.
(C) Left: example mEPSC traces from control (black) and shLRRTM4 (red)
electroporated cells on compressed timescale. Right: averaged mEPSC
traces on expanded timescale. Scaled, overlaid traces show normal decay
kinetics for both conditions.
(D) Summary of mEPSC frequencies plotted as cumulative probability distri-
butions of interevent intervals (IEIs) for control (black) and shLRRTM4 (red)
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the cell surface was able to bind LRRTM4 in solution, bath-
applied soluble GPC4 did not affect LRRTM4 clustering or
postsynaptic differentiation. In RGCs, soluble GPC4 induces
clustering of the glutamate receptor subunit GluR1 and
promotes excitatory synapse formation (Allen et al., 2012).
Cultured RGCs are more reluctant to form synapses than
hippocampal neurons, and soluble GPC4 may have more
pronounced effects on RGC synaptogenesis. Alternatively,
soluble GPC4 levels in hippocampal cultures may already be
saturating or secreted GPC4 may induce GluR1 clustering
through an LRRTM4-independent mechanism. It will be of
interest to determine whether GPC4 exerts these effects
through LRRTM4 in RGCs.
Role of the GPC4-LRRTM4 Interaction in Synapse
Development
GPC4 mRNA was expressed in neurons during synaptogene-
sis, GPC4 protein localized to excitatory presynaptic terminals,
and GPC4 was functionally required in neurons for LRRTM4’s
synaptogenic activity. The neuronal localization of GPC4 is in
agreement with previous studies that showed neuronal expres-
sion and axonal localization for other glypicans (Ivins et al.,
1997; Litwack et al., 1994, 1998; Saunders et al., 1997; Stipp
et al., 1994). Our findings do not rule out expression in astro-
cytes in early postnatal hippocampus (Allen et al., 2012), but
we conclude that GPC4 is primarily expressed in neurons
and presynaptically localized during synapse formation. Since
GPC4 is a GPI-anchored HSPG, additional, yet unknown,
signaling coreceptors may be required to promote LRRTM4-
mediated presynaptic differentiation. Our finding that excess
LRRTM4-Fc, but not GPC4-Fc, disrupted excitatory synapse
development in hippocampal neurons supports the existence
of a signaling coreceptor for GPC4. This result is reminiscent
of a previous study on the LRR protein NGL-1 and its GPI-
anchored axonal ligand Netrin-G1 (Lin et al., 2003). This study
concluded that Netrin-G1 is only part of the NGL-1 receptor,
since soluble NGL-1, but not soluble Netrin-G1, blocked
outgrowth of thalamic neurons. The identity of the putative
GPC4 coreceptor is unknown. Drosophila Dally-like binds to
LAR (leukocyte common antigen related), a receptor protein
tyrosine phosphatase (Johnson et al., 2006). Although LAR
was not identified in our GPC4-Fc pulldown experiment (data
not shown), it will be important to determine whether LAR is
a functional presynaptic GPC4 receptor.cells. Inset: quantification of meanmEPSC IEIs. LRRTM4 knockdown does not
affect mEPSC frequency (control 1006.5ms ± 136.2 [n = 16] versus shLRRTM4
953.0 ms ± 116.4 [n = 13]; p = 0.99, Student’s t test).
(E) Summary of mEPSC amplitudes plotted as cumulative probability distri-
butions. Inset: quantification of meanmEPSC amplitude. LRRTM4 knockdown
reduces mean mEPSC amplitude (control 12.64 ± 0.51 pA [n = 16] versus
shLRRTM4 10.28 ± 0.45 pA [n = 13]; p = 0.0023, Student’s t test).
(F) Dendrites of electroporated L2/3 cortical neurons were imaged in L2/3.
(G) LRRTM4 knockdown significantly decreases the density of dendritic pro-
trusions (control 0.66 ± 0.02 protrusions/mm [n = 56 dendrites, 4 animals]
versus shLRRTM4 0.54 ± 0.01 protrusions/mm [n = 78 dendrites, 4 animals]; p <
0.0001, Student’s t test). See also Figure S7. Bar graphs show mean ± SEM.
Scale bar represents 5 mm in (F).
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Synapse Organizer LRRTM4 Acts via HSPG GlypicanLRRTM4 regulates excitatory synapse development in vitro
and in vivo. Knockdown of LRRTM4 in cultured hippocampal
neurons decreased the density of functional excitatory synap-
ses. In vivo, LRRTM4 knockdown resulted in a significant
decrease in the density of dendritic spines, the predominant
sites of excitatory synapses in the CNS (Bourne and Harris,
2008). Importantly, we used sparse knockdown in subsets of
cells in both our in vitro and in vivo experiments. A recent study
showed that transcellular differences in the relative levels of
neuroligin-1 determine synapse number in vitro and in vivo
(Kwon et al., 2012), suggesting that neurons with lower neuro-
ligin-1 levels compared to their neighbors are less successful
in competing for synaptic inputs. Such a mechanism may
apply to LRRTMs as well. Despite the significant reduction in
dendritic spine density in L2/3 cortical neurons, we did not
detect a corresponding decrease in mEPSC frequency. Cortical
L2/3 neurons displayed a small decrease in mEPSC amplitude
after LRRTM4 knockdown, suggesting a decrease in AMPA
receptor (AMPAR) content. Since spine size and AMPAR
number are correlated (Matsuzaki et al., 2001; Takumi et al.,
1999), it is possible that a decrease in AMPAR content
after LRRTM4 knockdown results in smaller spines, which
may fall below the detection threshold in our image analysis.
Alternatively, LRRTM4 knockdown may predominantly affect
immature spines with low AMPAR content (‘‘silent’’ synapses),
resulting in decreased spine density but no effect on mEPSC
frequency. Our current image resolution was not sufficient
to rigorously analyze the morphology of individual spines.
Another possible explanation for the lack of decrease in
mEPSC frequency after LRRTM4 knockdown might be that
LRRTM4 regulates spine development in select dendritic
processes, rather than globally affecting spine density. Loss
of LRRTM1 affects VGlut1 clustering in select CA1 hippo-
campal laminae (Linhoff et al., 2009), suggesting that at least
some LRRTMs may have lamina-specific effects on synapse
development.
The reduction in synaptic strength after LRRTM4 knockdown
in vivo could be mediated by a direct role of LRRTM4 in AMPAR
trafficking. Both LRRTM4 and LRRTM3 were identified as com-
ponents of AMPAR complexes (Schwenk et al., 2012; Shanks
et al., 2012), and LRRTM2 binds GluR1 via its extracellular
domain in heterologous cells (deWit et al., 2009). A similar reduc-
tion in synaptic strength has been observed in GPC4 knockout
mice, which was attributed to decreased recruitment of the
AMPAR subunit GluR1 to synaptic sites (Allen et al., 2012). These
findings suggest that a disruption of the glypican-LRRTM4
interaction may lead to reduced recruitment or stabilization of
AMPARs at the synapse, resulting in a decrease in synaptic
strength.
Finally, genome-wide association studies have linked GPC1
and GPC6 to ADHD, neuroticism, and schizophrenia (Calboli
et al., 2010; Lesch et al., 2008; Potkin et al., 2009). The associa-
tion of glypicans with these nervous system disorders indicates
that glypicans may be important for proper brain function.
The identification of the trans-synaptic glypican-LRRTM4 inter-
action as a key regulator of excitatory synapse development
should provide an avenue for a deeper understanding of these
disorders.EXPERIMENTAL PROCEDURES
Neuronal Cultures
Hippocampal neurons were cultured from P0 Long-Evans rats (Charles River)
and plated on poly-D-lysine-coated (Millipore) and laminin-coated (Invitrogen)
chamber slides (Nalge Nunc International). Neurons were maintained in
Neurobasal-A medium (Invitrogen) supplemented with B27, glucose, gluta-
max, penicillin/streptomycin (Invitrogen), and 25 mM b-mercaptoethanol.
Neurons were transfected using calcium phosphate at 7 DIV. For knockdown
experiments, neurons were electroporated at time of plating using a Bio-Rad
Gene Pulser Xcell. For Fc treatments of neuronal cultures, Fc proteins
(10 mg/ml final concentration) were added to the culture media. For 6-day
treatments, half the media was replaced after 3 days with fresh feeding media
containing the same final concentration Fc protein.
Immunocytochemistry
Neurons were fixed in 4% paraformaldehyde, 4% sucrose in PBS, washed in
PBS, and blocked in 3% BSA, 0.2% Triton X-100 in PBS. Primary antibodies
were the following: goat anti-GFP (Abcam), mouse anti-PSD-95 (Thermo
Scientific/Affinity BioReagents), mouse anti-Prox1 (Millipore), guinea pig
anti-VGlut1 (Millipore), mouse anti-gephyrin and guinea pig anti-VGAT
(Synaptic Systems), mouse anti-LRRTM4 (clone N205B/22, UC Davis/NIH
Neuromab), sheep anti-LRRTM4 (R&D Systems), rabbit anti-GPC4 (aa 88–
101; Immundiagnostik), rabbit anti-GluR1 (Calbiochem), rabbit anti-synapsin
(Millipore), chicken anti-MAP2 (Sigma), mouse anti-myc 9E10 (Santa Cruz
Biotechnology), mouse anti-HA (Covance), mouse anti-FLAG M2 (Sigma),
and mouse anti-heparan sulfate delta (3G10 epitope) (USBiological).
Fluorophore-conjugated secondary antibodies were from Jackson Immuno-
Research or Invitrogen. Quantification of synapse density was performed
blind to condition as described in de Wit et al. (2009).
Cell Surface Binding Assays
HEK293T cells were transfected with expression constructs using Fugene6
(Promega). Twenty-four hours after transfection, the cells were incubated
with Fc proteins (10 mg/ml in Dulbecco’s modified Eagle’s medium [DMEM]
supplemented with 20 mM HEPES [pH 7.4]) for 1 hr at RT. After two brief
washes with DMEM/20 mM HEPES (pH 7.4), cells were fixed and immuno-
stained as above.
Mixed-Culture Assays
Mixed-culture assays were performed as described in Biederer and Scheiffele
(2007). Briefly, HEK293T cells were transfected with the appropriate plasmid
using Fugene6 (Promega), trypsinized or mechanically dissociated, and cocul-
tured with hippocampal neurons (7 or 14 DIV) for 8, 12, or 24 hr depending on
the experiment. For analysis of the effect of heparinase III treatment, hippo-
campal neurons (7 DIV) were treated with 1 U/ml heparinase III (Sigma) or
vehicle (20 mM Tris-HCl [pH 7.5], 0.1 mg/ml BSA, 4 mM CaCl2) for 2 hr at
37C. Cells were washed twice with hippocampal feeding media and subse-
quently cocultured with transfected 293T cells for an additional 8 hr. For
competition experiments with heparan sulfate, hippocampal neurons (7 DIV)
were cocultured with transfected 293T cells for 12 hr in the presence of hep-
aran sulfate (0.5 mg/ml; Sigma) or vehicle (PBS). For competition experiments
with Fc proteins, Fc control, Nrx1b(S4)-Fc, or GPC4-Fc proteins (final con-
centration 50 mg/ml) were added to the mixed cultures, 45 min after plating
the 293T cells on DIV7 neurons. After 12 hr of coculturing, the mixed-culture
assays were fixed and stained as above.
In Utero Electroporation
Cortices of 15.5-day-old embryos (E15.5) of timed pregnant CD1 mice
(Charles River) were unilaterally electroporated with control or shLRRTM4
FCK0.4GW vector plasmid. Briefly, the dam was anesthetized with isoflurane
and the uterus exposed. A solution of DNA and 0.01% fast green dye was in-
jected into the embryonic lateral ventricle with a beveled glass micropipette.
The embryo’s head was positioned between the paddles of pair of platinum
tweezer-type electrodes (BTX) with the cathode lateral to the filled ventricle,
and five 75 ms, 40 V pulses were delivered at 1 Hz by a CUY21 electroporatorNeuron 79, 696–711, August 21, 2013 ª2013 Elsevier Inc. 709
Neuron
Synapse Organizer LRRTM4 Acts via HSPG Glypican(BEX). After electroporation, the uterus was replaced, the incision sutured
closed, and the dam allowed to give birth normally.
See the Supplemental Experimental Procedures for more information.
SUPPLEMENTAL INFORMATION
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